1 Why some countries but not others? Urbanisation, GDP and endemic disease predict

- 2 global SARS-CoV-2 excess mortality patterns.
- 3
- 5 Luke Yates¹

6 Affiliations:

- ⁷ ¹School of Natural Sciences, University of Tasmania, Hobart Australia 7001.
- 8 ²Healthy Landscapes Research Group, University of Tasmania, Hobart Australia 7001
- 9
- 10 <u>*Nick.FountainJones@utas.edu.au</u>
- 11

12 Abstract

13	The global impact of the SARS-CoV-2 pandemic has been uneven, with some regions
14	experiencing significant excess mortality while others have been relatively unaffected. Yet
15	factors which predict this variation remain enigmatic, particularly at large spatial scales. We
16	used spatially explicit Bayesian models that integrate socio-demographic and endemic
17	disease data at the country level to provide robust global estimates of excess SARS-CoV-2
18	mortality (P scores) for the years 2020 and 2021. We find that gross domestic product (GDP),
19	spatial patterns and urbanization are strong predictors of excess mortality, with countries
20	characterized by low GDP but high urbanization experiencing the highest levels of excess
21	mortality. Intriguingly, we also observed that the prevalence of malaria and human
22	immunodeficiency virus (HIV) are associated with country-level SARS-CoV-2 excess
23	mortality in Africa and the Western Pacific, whereby countries with low HIV prevalence but
24	high malaria prevalence tend to have lower levels of excess mortality. While these
25	associations are correlative in nature at the macro-scale, they emphasize that patterns of
26	endemic disease and socio-demographic factors are needed to understand the global
27	dynamics of SARS-CoV-2.
28	Key words: COVID-19, human immunodeficiency virus (HV), malaria, macroecology,

29 spatial model

31 Introduction

32	Since the emergence of the SARS-CoV-2 pandemic in December 2019, there has been
33	substantial interest in understanding the determinants of disease patterns and accurately
34	assessing the true impact of this worldwide disaster. There have been a wide variety of
35	approaches to estimating the mortality associated with SARS-CoV-2, but in each case,
36	estimates of the true death toll have likely been orders of magnitude higher than reported
37	deaths. Excess mortality, the difference in deaths due to a crisis compared to those expected
38	under normal conditions [1], provides a more reliable estimate of COVID-19 deaths than
39	reported deaths [2]. However, the factors shaping the heterogeneity of estimates of excess
40	deaths across countries remain obscure.
41	Global estimates for the first epidemic waves in 2020/2021 range from 14.8 [2] to 18.2
42	million excess deaths [3], dwarfing the 5.94 million reported deaths for the same period. For
43	example, the World Health Organization (WHO) estimated Indonesia to have 1.03 million
44	excess deaths up until December 2021 (credible interval (CI) 0.75-1.29 million) whereas 0.23
45	million excess deaths were estimated in Pakistan (CI 0.04-0.4 million) [2], even though the
46	population sizes of these countries are comparable. Africa has experienced much lower
47	excess mortality compared to most other regions [2-5]. Deficiencies in the input data in
48	developing countries may underly some of this variation, but these estimates are congruent
49	with cross-sectional studies and reports [e.g., 6].
50	Comparing excess mortality estimates across countries is a challenging task as raw estimates

51 are strongly dependent on population size and age structure of each country [2,7]. For

52 example, larger populations with higher proportions of older people will have higher number

53 of expected deaths compared to countries with smaller younger populations. To facilitate

54 cross-country comparisons, estimates of excess deaths are often normalized by the expected

55 number of deaths (from all causes) across a period of time. The measurement of excess 56 deaths, referred to as a P-score [7], takes into account both the population size and age 57 structure (see *Methods*). For instance, if 100 deaths were anticipated but the actual number 58 reached 150, resulting in 50 excess deaths, the P-score would be calculated as 50% [7]. Put 59 another way, if a country had a P-score of 50% for a year then the reported death count was 60 50% higher than the expected death count that year. Recent (as of February 2023) P-score 61 estimates from the WHO have provided important insights into the relative toll of the 62 pandemic across countries, with smaller countries in the Americas suffering relatively more 63 excess deaths (highest P-scores), even though they experienced fewer absolute deaths 64 compared to larger countries [2]. For example, Peru had an estimated P-score of 97% or 65 effectively a doubling of deaths during the first waves of the pandemic [2]. Other countries, 66 such as Australia where infection rates were low were estimated to have negative values as 67 there were actually fewer deaths during these years than expected [2]. 68 Clearly, differences in pandemic response explain some variation in global P-Score estimates 69 but these are not sufficient to explain the general patterns [2]. Here we build a fully 70 probabilistic model accounting for uncertainties in P-score estimates to test if socio-71 demographic, economic and patterns of endemic disease could help predict these disparate 72 estimates of excess mortality across countries. While P-scores control for age structure of a 73 population, age is a well-known risk factor for mortality, some countries with larger portions 74 of the population > 70 y.o. are likely to experience higher mortality than countries with fewer 75 people in this age bracket [e.g., 8]. As P-scores capture direct and indirect SARS-CoV-2 76 deaths (e.g., because patients could not access treatment that would be otherwise available), 77 the prevalence of non-communicable conditions such as heart disease [9] may also play a role 78 in shaping these excess deaths. Economic variables such as gross domestic product (GDP) 79 [30] and health spending may also impact mortality rates as countries with high GDP and

80	health spending may lower mortality risks through, for example, better treatment. Countries
81	with high population density and urbanisation may also experience higher mortality as
82	transmission may be facilitated in these conditions [10] or lower, because urban populations
83	tend to have better access to health facilities [11]. Further, our previous work has also found
84	that variation in the prevalence of endemic pathogens including malaria (Plasmodium sp.),
85	common intestinal parasitic worms (e.g., Trichuris trichiura, the causative agent of
86	ascariasis) and human immunodeficiency virus (HIV) played a surprisingly important role in
87	predicting variation in SARS-CoV-2 reported deaths [12]. For example, countries with
88	relatively high prevalence of endemic malaria had reduced numbers of deaths, whereas
89	countries with higher HIV prevalence had higher numbers of reported deaths (while
90	controlling for other factors such as the mean age of the country) [12].
91	Spatial relationships are also likely to be important in explaining variation in P-scores and
91 92	Spatial relationships are also likely to be important in explaining variation in P-scores and need to be accounted for in global models [e.g., 13]. For example, regions or countries closer
91 92 93	Spatial relationships are also likely to be important in explaining variation in P-scores and need to be accounted for in global models [e.g., 13]. For example, regions or countries closer in space may have similar P-scores due to similar epidemic trajectories [14]. High
91 92 93 94	Spatial relationships are also likely to be important in explaining variation in P-scores and need to be accounted for in global models [e.g., 13]. For example, regions or countries closer in space may have similar P-scores due to similar epidemic trajectories [14]. High connectivity between neighbouring countries could also facilitate the spread of the virus and
91 92 93 94 95	Spatial relationships are also likely to be important in explaining variation in P-scores and need to be accounted for in global models [e.g., 13]. For example, regions or countries closer in space may have similar P-scores due to similar epidemic trajectories [14]. High connectivity between neighbouring countries could also facilitate the spread of the virus and increase mortality. International air travel is also known to facilitate SARS-CoV-2 spread
91 92 93 94 95 96	Spatial relationships are also likely to be important in explaining variation in P-scores and need to be accounted for in global models [e.g., 13]. For example, regions or countries closer in space may have similar P-scores due to similar epidemic trajectories [14]. High connectivity between neighbouring countries could also facilitate the spread of the virus and increase mortality. International air travel is also known to facilitate SARS-CoV-2 spread among countries [13,15,16], and countries with high air travel connectivity with other
91 92 93 94 95 96 97	Spatial relationships are also likely to be important in explaining variation in P-scores and need to be accounted for in global models [e.g., 13]. For example, regions or countries closer in space may have similar P-scores due to similar epidemic trajectories [14]. High connectivity between neighbouring countries could also facilitate the spread of the virus and increase mortality. International air travel is also known to facilitate SARS-CoV-2 spread among countries [13,15,16], and countries with high air travel connectivity with other countries may have increased numbers of introduction events which may result in higher
91 92 93 94 95 96 97 98	Spatial relationships are also likely to be important in explaining variation in P-scores and need to be accounted for in global models [e.g., 13]. For example, regions or countries closer in space may have similar P-scores due to similar epidemic trajectories [14]. High connectivity between neighbouring countries could also facilitate the spread of the virus and increase mortality. International air travel is also known to facilitate SARS-CoV-2 spread among countries [13,15,16], and countries with high air travel connectivity with other countries may have increased numbers of introduction events which may result in higher mortality. Countries with high connectivity also tended to have the earliest outbreaks of the
91 92 93 94 95 96 97 98 99	Spatial relationships are also likely to be important in explaining variation in P-scores and need to be accounted for in global models [e.g., 13]. For example, regions or countries closer in space may have similar P-scores due to similar epidemic trajectories [14]. High connectivity between neighbouring countries could also facilitate the spread of the virus and increase mortality. International air travel is also known to facilitate SARS-CoV-2 spread among countries [13,15,16], and countries with high air travel connectivity with other countries may have increased numbers of introduction events which may result in higher mortality. Countries with high connectivity also tended to have the earliest outbreaks of the virus [17].

100 In this study, we introduce a Bayesian model-based framework with the aim to discover the 101 potential drivers behind the variations in excess deaths across countries. By utilizing this 102 model-based approach, we illuminate factors that contribute to the diverse severity of the 103 pandemic's consequences worldwide.

104 Methods

105 Data retrieval

106	We extracted P-score estimates from the WHO excess mortality code base on the 3 rd of
107	March 2023 (the https://github.com/WHOexcessc19/Codebase). We computed the posterior
108	mean and its standard error for the average P-score estimates across the 24 months spanning
109	2020 and 2021. We used only data for the first wave of SARS-CoV-2 to examine infection
110	patters without the influence of the variable roll-out of vaccines. We also used the WHO
111	transmission classification scheme (i.e., countries with community transmission, clusters of
112	cases only, sporadic cases and no cases) to account for differences in pandemic response (as
113	of 29 th of January 2021, the midpoint of our excess mortality estimates).
114	We leveraged the predictor variables collated previously [see 12 for further details]. Briefly,
115	we extracted demographic and economic variables from the World Bank dataset
116	(https://data.worldbank.org/) for each country. These variables include per capita GDP (in
117	current USD averaged across 2014-2019), percent of the population living in urban areas
118	(hereafter percent urban). Global health spending estimates (USD) are calculated by the
119	World Health Organization and include healthcare goods and services consumed each year.
120	To analyse the importance of spatial patterns to P-score estimates we constructed a lagged P-
121	score variable based on a neighbourhood matrix. To construct the neighbourhood matrix, we
122	extracted centroid coordinates of countries and generated spatial neighbourhood matrix based
123	on the mean P-score estimate using the spdep package in R [18]. To capture the role of
124	country-level connectivity in predicting P-scores, we incorporated the 2007 air connectivity
125	index [16]. We attempted to include an intrinsic spatial conditional autoregressive (iCAR)
126	term to our model, yet we could not attain model convergence with this extra complexity.

127 We downloaded the mean estimate of prevalence of 14 endemic diseases in each country

128 (Table S1) based on 2019 data from the Institute for Health Metrics and Evaluation (IHME)

129 Global Burden of Disease (GBD) database (https://www.healthdata.org/research-

- 130 <u>analysis/gbd</u>). As many of the country-level disease prevalence estimates were correlated, we
- 131 conducted principal component analysis (PCA) and we used the top three resultant
- 132 orthogonal principal components as predictors in our models. As malaria and HIV were not
- 133 correlated with any of the principal components, we included these variables separately. To
- 134 measure overall infectious disease burden, we also extracted estimates of years of life lost
- 135 (YLLs) for infectious diseases combined in each country in 2019 using the GBD data. We
- 136 extracted diabetes prevalence and the average cardiovascular death rate for each country in
- 137 2019 from the GBD also. See Table S1 for a complete list of predictors used.
- 138 We imputed missing data for both datasets dataset using classification and regression trees as
- implemented in the multivariate imputation by chained equations (MICE) package [19]. We
- 140 generated ten separate multiple imputations and combined the posterior distributions across
- 141 the ten corresponding model fits to marginalise over the uncertainty of the replacement
- 142 values. We screened variables for collinearity by calculating Pearson's correlation
- 143 coefficient (ρ) and for correlated pairs excluded the variable with the highest correlation
- 144 across the complete dataset.

145 Bayesian modelling

We modelled P-score variation globally using generalised additive models (GAM) with aGaussian error distribution to facilitate the inclusion of response errors (i.e., the uncertainty

- 148 of the P-score estimates) and since the P-scores values are naturally unconstrained. The
- 149 advantage of GAMs over linear models is their flexibility to capture a wide range of non-
- 150 linear functional forms using splines while mitigating overfitting through smoothing (we set

151 the maximal basis dimensions of the splines to 6 to flexibly capture non-linear relationships

- 152 while keeping the effective model complexity under control). Specifically, our models
- 153 quantified the probability of observing P-scores (y_i) in country *i* given by:

$$p(y_i \mid \mu_{i}, \sigma_i, se_i) = N(\mu_{i}, \sigma_i^2 + se_i^2)$$

where $se_i = se(y_i)$ is the standard error of the response and μ_i and σ_i^2 are the modelled mean and variance, respectively. Models for each of the distributional parameters are given by:

$$\mu_{i} = \beta_{0} + b_{\text{region}[i]} + \beta_{\text{trans}[i]} + \sum_{k}^{p} f_{k}(X_{ki}) (2)$$
$$\log \sigma_{i} = \alpha_{0} + a_{\text{region}[i]}(3)$$

where α_0 and β_0 are global intercepts, a and b are region-level (random) intercepts, β_{trans} is a 156 157 fixed effect for transmission type, p number of predictors included in the model and $f_k(X_{ki})$ 158 are smooth spline terms for each continuous predictor X_k . The region-level intercepts $(a_{region[i]}, b_{region[i]})$ were drawn from a bivariate normal distribution with an estimated 159 160 three-parameter covariance matrix. The basis elements for each thin plate smoothing spline 161 were generated using the R package mgcv [20] and the corresponding regression coefficients 162 were drawn from a normal distribution parametrised by an estimated smoothing 163 hyperparameter.

164 All models were fit in a Bayesian framework using Hamiltonian Monte Carlo (HMC)

165 methods [21] and 'no U-turn sampling' (NUTS, [22]), as implemented in the R package

166 'brms' [23]. We ran four chains of 12000 iterations, using weakly informative priors---the

167 prior for the smoothing hyperparameter was half student-t distribution (df = 3, scale = 2.6),

168 and inferences proved robust to changes in the choice of scale. To establish chain

169 convergence, we used the rank-normalised \hat{R} statistic ($\hat{R} < 1.01$) [24] as well as visual

inspection. We validated the model by comparing pointwise posterior-predictive intervals tothe observed P-scores for each country [25].

172	To interrogate our model, we computed conditional effects for each covariate. For the
173	numeric variables, we computed the estimated change in response (centred on the posterior-
174	predictive mean) as a function of changes in the value of a given predictor (centred on the
175	global mean) while holding all other variables at their global means. Variables were
176	considered strong predictors of P-scores if the 90% credible interval (CI) did not include 0.
177	Variables where this was true for a smaller portion of the range were identified as weaker
178	variables (variables where all values of the CI included 0). To test the utility of adding
179	endemic disease variables to our macroecological models, we evaluated model performance
180	using approximate leave-one-our cross validation (LOO, [26]) an estimate of relative
181	expected Kullback-Leibler discrepancy and compared the model both with and without the
182	inclusion of endemic pathogens. We also compared model performance by region. Our
183	complete workflow and data are available on github:
184	(https://github.com/nfj1380/covid19_macroecology).
185	
-	

- -

186 **Results**

187

Our model was able to predict global P-score variation remarkably well with mean observed P-scores from 175 out of 181 countries inside the model credible intervals (Fig. 1). Our model underestimated excess mortality for five countries and only overestimated P-scores from Togo. Our model could not predict the P-score for Peru (the highest mean P-score calculated, Fig. 1 inset) but our predictive performance was high for countries with very low or negative P-scores. Our models also underestimated excess mortality in Guam, Oman,

- 194 Andorra and Armenia (Fig. S1). There was overall no difference in model performance
- 195 across regions, but countries in the Americas had much higher uncertainty in P-score
- 196 estimates compared to the other regions. (Fig. 1).



Fig. 1: Posterior predictive performance of our P-score model for each country and (inset) the global distribution of mean P-scores across

countries. Countries are grouped by region and ordered by predicted values (lowest to highest). Black dots are the observed values for each
 country and the trend line is the median posterior estimate of the models. Credible intervals (CIs) are coloured by region, with the 50% and 95%

202 CIs depicted by thick and thin lines, respectively. See Fig. S1 for predictions with each country labelled.

We found a mix of population, spatial patterns and endemic disease that best predicted Pscore variation in our models (Fig. 2). Though important at individual or within country
scales, variables such as proportion over 65 y.o., population density and air-connectivity were
less important at global scales (Fig. 2a). We also did not see a signature of diabetes
prevalence or cardiovascular disease impacting P-score estimates (Fig. 2a, see Fig S2 for the
conditional effects plots).

209 Per-capita GDP and percent urban were strong predictors of P-score variation (Fig. 2a/b).

210 Wealthier countries with a per-capita GDP >\$20,000 had decreased P-scores (while

211 controlling for all other predictors in the model, Fig. 2b). GDP decreased excess mortality by

212 up to 10% in countries with a GDP of ~\$60,000 (e.g., USA, Iceland, and Singapore).

213 Conversely, countries with >60% urban population had higher P-scores (Fig. 2b). Spatial

214 patterns played a role and the effect was non-linear (Fig. 2a/b). Countries with neighbours

215 having average P-scores >12 also exhibited higher P-scores (Fig. 2b).

216 We also detected divergent (but weaker) relationships with malaria and HIV prevalence on P-217 scores (Fig. 2a). While holding all other variables in the model at their mean value, countries 218 with relatively high prevalence of malaria had decreased P-scores, whereas countries with 219 relatively high HIV prevalence had higher P-scores. The estimated LOO scores indicated that 220 retaining endemic disease variables in the model did not improve model fit overall (ELPD 221 difference = -1.4, SE = 4.4), although including endemic disease did improve predictions in 222 the Western Pacific (Fig. 2c). There was also some evidence that the fit was improved by 223 endemic disease in Africa but the LOO scores were highly variable which could indicate that 224 we are missing important variables in this region. For Europe and the Americas in contrast, 225 model fit was improved by not including the endemic disease variables (i.e., LOO model

- 226 difference scores above 0). Collectively, there appears some regional scale context-dependent
- 227 relationships between SARS-CoV-2 P-scores and endemic disease.



230 Fig 2: Conditional effects of model predictors on the expected change in global P-scores. a) 231 and direction of covariate effects on P-scores. Pos = positive, Neg = negative. Covariates 232 without a corresponding circle (i.e., blank) had little impact on P-score estimates (see Fig. 233 S2). b-f) Conditional plots showing the expected difference in P-scores as a function of the 234 difference between a given covariate value and the mean observed covariate vales (CIs have a 235 width of 0 at the mean, see *Methods*). span the predictors included in the model. Solid lines 236 denote the posterior means and the associated intervals (dashed lines) denote the 90% 237 credible intervals (CIs). Predictors are colour-coded based on variable type (dark blue = 238 associated with a country's economic capacity, light red = country level pathogen prevalence 239 estimate, light grey = estimated prevalence of non-infectious disease, light green= spatial 240 variable, purple = population characteristic. Spatial: estimates of cases in neighbouring 241 countries. HIV: Human immunodeficiency virus. (see Table S1 for details). g) Leave one out 242 (LOO) comparisons of our model with all co-variates compared to a model leaving out the 243 endemic disease variables summed across regions. Region level estimates not overlapping the 244 0 LOO difference were considered significant. W.o = without.

246 Discussion

247

248 Our study provides some important insights into the divergent impacts of the SARS-CoV-2 249 pandemic. Our Bayesian analytical approach combined with robust estimates of excess deaths 250 from the WHO revealed that GPD, urbanisation and spatial patterns played an important role 251 in predicting excess mortality across countries. We also found that malaria and HIV were 252 associated with excess deaths, particularly in the Western Pacific and African regions, but not 253 necessarily in other regions of the world. Studies at this scale, while necessarily associative, 254 can help identity plausible drivers of variation in SARS-CoV-2 mortality at large spatial 255 scales.

256

257 We identified that highly urban countries with low GDP and surrounded by countries with 258 high P-Scores had the highest levels of excess mortality during the first waves of the 259 pandemic. Endemic disease patterns also had some association, but comorbidities such as 260 diabetes prevalence and proportion of the population > 65 y.o. were less relevant at the scale 261 of our analysis. The relationship between GDP and SARS-CoV-2 mortality has generally 262 been found to be positively correlated with the number of reported deaths higher in countries 263 with higher GDP [e.g., 27]. Our model using the more robust P-score estimates of excess 264 mortality suggest the opposite trend; potentially as our estimates are less-impacted by 265 reporting biases in countries with fewer resources. GDP is strongly correlated with health 266 spending, so it is possible that the quality of health care afforded by countries with high GDP 267 is associated with reduced excess mortality. However, even after accounting for GPD, the 268 burden of excess mortality is not shared evenly. Highly urban populations are known to be 269 vulnerable to SARS-CoV-2 mortality as urban areas are densely populated and are travel

270 hubs, both of which facilitate transmission [10,12,16,27]. Despite the benefits of living in

271 cities, such as better access to medical resources, our study demonstrates that urban areas face

amplified SARS-CoV-2-related mortality [11].

273

274 Highly urban countries are often more connected to other countries, yet higher air 275 connectivity alone did not explain P-score variation in our model. Spatial relationships as 276 well as regional variability were more important and similar results have been found in 277 models focusing on global patterns of confirmed deaths [12]. In our analysis, a clear 278 threshold emerged indicating a spatial effect, where mean P-scores increased when the 279 average of neighbouring countries exceeded approximately 10. This finding suggests 280 geographically constrained patterns, with countries experiencing high transmission and 281 mortality influencing neighbouring P-scores through cross-border transmission.

282

283 We also provide further evidence for the effect of endemic pathogen prevalence on global 284 SARS-CoV-2 mortality with countries with lower malaria prevalence but higher HIV 285 prevalence tending to have higher P-scores. While the effect at a global level was marginal, 286 our interrogation of regional level patterns found that endemic pathogens were associated 287 with P-score patterns in the regions with high burdens of endemic disease. Our findings are 288 similar to other studies modelling deaths at this scale and our previous work [12,16]. In these 289 regions, coinfections with either of these pathogens and SARS-CoV-2 were common and 290 coinfection can impact the severity of SARS-CoV-2 [28–30]. For example, 291 immunocompromised HIV patients can face a higher risk of severe SARS-CoV-2 infection 292 [31]. At a coarser scale, countries in Africa with high-levels of mortality also had the highest 293 prevalence of HIV [16]. Additionally, there is evidence suggesting that malaria can influence

294	the mortality rates of SARS-CoV-2 by mitigating the severity of the illness [29,32]. For
295	instance, a study conducted on healthcare workers in India revealed that individuals
296	coinfected with malaria and SARS-CoV-2 experienced an average recovery period that was
297	eight days shorter than those who were infected with SARS-CoV-2 alone [29].

298

299 Though our model for the most part could predict country-level P-scores well, it is important 300 to acknowledge that this was not the case for all countries. For example, the P-score for Peru 301 exceeded our model estimates. Why Peru is globally unique is unclear, but may be linked to 302 failures in the health system coupled with diverse populations with high levels of poverty 303 [33]. Although we gathered a diverse range of predictors, the dataset is not comprehensive, 304 and we may have missed important axes of variation. Our objective was to include as many 305 countries as possible in the analysis while minimizing missing data. Our data was also 306 aggregated at the country-level and we possibly missed important variation within countries 307 that may provide high resolution predictions of SARS CoV-2 mortality. Moreover, while our 308 model was able to propagate the estimated uncertainty with the WHOs modelled P-scores, it 309 is important to recognise some features of WHOs generation of the P-scores themselves. The 310 WHO found that tracking excess mortality directly in some parts of the world, particularly in 311 sub-Saharan Africa, was not possible and within-country estimates relied on statistical 312 models [2]. We urge caution when interpreting our cross-country models in the region. Still 313 as reported deaths data are likely a severe undercount in sub-Saharan Africa [2,34], model-314 based P-score estimates provide the most reliable estimates of SARS-CoV-2 mortality in the 315 region.

316

317 Our study highlights factors associated with variation in excess mortality across countries and

- 318 provides insights into why some countries were impacted more by the pandemic than others.
- 319 By understanding the predictors of P-score variation across countries and gaining insights
- 320 into the differential impacts of the pandemic, we may be able to better inform global
- 321 strategies for outbreak management and response. For example, our model estimates suggest
- 322 that targeting medical resources to highly urban countries with low GDP and high HIV
- 323 prevalence may reduce mortality during future outbreaks. Future investigations should aim to
- 324 explore these global factors using increasingly accurate mortality estimates and consider the
- 325 dynamics of new waves of SARS-CoV-2.

326 Data availability statement

- 327 All data and code used to perform the analyses presented in this paper are available on
- 328 Github: https://github.com/nfj1380/covid19_macroecology

329 Acknowledgements

- 330 This project was supported by an Australian Research Council Discovery Project Grant
- 331 (DP190102020).
- 332 Conflicts of interest
- 333 None to declare

335 References

- 336 1. Checchi F, Roberts L. In press. A primer for non-epidemiologists.
- Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J. 2023
 The WHO estimates of excess mortality associated with the COVID-19 pandemic.
 Nature 613, 130–137. (doi:10.1038/s41586-022-05522-2)
- Wang H *et al.* 2022 Estimating excess mortality due to the COVID-19 pandemic: a
 systematic analysis of COVID-19-related mortality, 2020–21. *The Lancet* **399**, 1513–
 (doi:10.1016/S0140-6736(21)02796-3)
- 343 4. 2023 The pandemic's true death toll. *The Economist.* See
 344 https://www.economist.com/graphic-detail/coronavirus-excess-deaths-estimates
 345 (accessed on 24 May 2023).
- Bouba Y, Tsinda EK, Fonkou MDM, Mmbando GS, Bragazzi NL, Kong JD. 2021 The
 Determinants of the Low COVID-19 Transmission and Mortality Rates in Africa: A Cross Country Analysis. *Front Public Health* 9, 751197. (doi:10.3389/fpubh.2021.751197)
- Salyer SJ *et al.* 2021 The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study. *The Lancet* **397**, 1265–1275. (doi:10.1016/S0140-6736(21)00632-2)
- 352 7. In press. A pandemic primer on excess mortality statistics and their comparability across
 353 countries. *Our World in Data*. See https://ourworldindata.org/covid-excess-mortality
 354 (accessed on 24 May 2023).
- Sorci G, Faivre B, Morand S. 2020 Explaining among-country variation in COVID-19
 case fatality rate. *Sci Rep* 10, 18909. (doi:10.1038/s41598-020-75848-2)
- Han L, Zhao S, Li S, Gu S, Deng X, Yang L, Ran J. 2023 Excess cardiovascular
 mortality across multiple COVID-19 waves in the United States from March 2020 to
 March 2022. *Nat Cardiovasc Res* 2, 322–333. (doi:10.1038/s44161-023-00220-2)
- 360 10. González-Val R, Sanz-Gracia F. 2022 Urbanization and COVID-19 incidence: A cross 361 country investigation. *Papers in Regional Science* 101, 399–415.
 362 (doi:10.1111/pirs.12647)
- 363 11. Scheil-Adlung X. 2015 Global evidence on inequities in rural health protection □: new
 364 data on rural deficits in health coverage for 174 countries. *ILO Working Papers*
- 365 12. Fountain-Jones NM, Yates L, Flies E, Flies A, Carver S, Charleston M. 2021 Patterns of
 366 SARS-CoV-2 exposure and mortality suggest endemic infections, in addition to space
 367 and population factors, shape dynamics across countries. *medRxiv*,
 368 2021.07.12.21260394. (doi:10.1101/2021.07.12.21260394)
- 369 13. Krisztin T, Piribauer P, Wögerer M. 2020 The spatial econometrics of the coronavirus pandemic. *Lett Spat Resour Sci* 13, 209–218. (doi:10.1007/s12076-020-00254-1)
- 14. Lacasa L, Challen R, Brooks-Pollock E, Danon L. 2020 A flexible method for optimising
 sharing of healthcare resources and demand in the context of the COVID-19 pandemic. *PLOS ONE* 15, e0241027. (doi:10.1371/journal.pone.0241027)

- 374 15. Zhong L, Diagne M, Wang W, Gao J. 2021 Country distancing increase reveals the
 are effectiveness of travel restrictions in stopping COVID-19 transmission. *Commun Phys* 4, 1–12. (doi:10.1038/s42005-021-00620-5)
- 377 16. Zhang F *et al.* 2021 Predictors of COVID-19 epidemics in countries of the World Health
 378 Organization African Region. *Nat Med* 27, 2041–2047. (doi:10.1038/s41591-021-01491379 7)
- 380 17. Bickley SJ, Chan HF, Skali A, Stadelmann D, Torgler B. 2021 How does globalization
 affect COVID-19 responses? *Globalization and Health* 17, 57. (doi:10.1186/s12992-021 00677-5)
- Bivand R, Piras G. 2015 Comparing Implementations of Estimation Methods for Spatial
 Econometrics. *Journal of Statistical Software* 63, 1–36. (doi:10.18637/jss.v063.i18)
- 385 19. Azur MJ, Stuart EA, Frangakis C, Leaf PJ. 2011 Multiple imputation by chained
 a86 equations: what is it and how does it work? *Int J Methods Psychiatr Res* 20, 40–49.
 a87 (doi:10.1002/mpr.329)
- 388 20. Wood S. In press. Generalized Additive Models: An Introduction with R, Second Edition 389 . See https://www.routledge.com/Generalized-Additive-Models-An-Introduction-with-R390 Second-Edition/Wood/p/book/9781498728331 (accessed on 8 July 2021).
- 391 21. Neal RM. 2011 MCMC using Hamiltonian dynamics. *arXiv:1206.1901 [physics, stat]* 392 (doi:10.1201/b10905)
- 393 22. Homan MD, Gelman A. 2014 The No-U-turn sampler: adaptively setting path lengths in
 394 Hamiltonian Monte Carlo. *J. Mach. Learn. Res.* 15, 1593–1623.
- 395 23. Bürkner P-C. 2017 brms: An R Package for Bayesian Multilevel Models Using Stan.
 396 *Journal of Statistical Software* 80, 1–28. (doi:10.18637/jss.v080.i01)
- 24. Vehtari A, Gelman A, Simpson D, Carpenter B, Bürkner P-C. 2021 Rank-Normalization,
 Folding, and Localization: An Improved R[^] for Assessing Convergence of MCMC.
 Bayesian Analysis 1, 1–38. (doi:10.1214/20-BA1221)
- 400 25. Gabry J, Simpson D, Vehtari A, Betancourt M, Gelman A. 2019 Visualization in Bayesian
 401 workflow. *Journal of the Royal Statistical Society: Series A (Statistics in Society)* 182,
 402 389–402. (doi:10.1111/rssa.12378)
- 403 26. Vehtari A, Gelman A, Gabry J. 2017 Practical Bayesian model evaluation using leave404 one-out cross-validation and WAIC. *Stat Comput* 27, 1413–1432. (doi:10.1007/s11222405 016-9696-4)
- 406 27. Skórka P, Grzywacz B, Moroń D, Lenda M. 2020 The macroecology of the COVID-19
 407 pandemic in the Anthropocene. *PLOS ONE* 15, e0236856.
 408 (doi:10.1371/journal.pone.0236856)
- 409 28. Bradbury RS, Piedrafita D, Greenhill A, Mahanty S. 2020 Will helminth co-infection
 410 modulate COVID-19 severity in endemic regions? *Nat Rev Immunol* 20, 342.
 411 (doi:10.1038/s41577-020-0330-5)
- 412 29. Mahajan NN *et al.* 2021 Co-infection of malaria and early clearance of SARS-CoV-2 in
- 413 healthcare workers. *Journal of Medical Virology* **93**, 2431–2438.
- 414 (doi:https://doi.org/10.1002/jmv.26760)

- 30. Miguel DC, Brioschi MBC, Rosa LB, Minori K, Grazzia N. 2021 The impact of COVID-19
 on neglected parasitic diseases: what to expect? *Trends in Parasitology* 37, 694–697.
 (doi:10.1016/j.pt.2021.05.003)
- 418 31. Huang J *et al.* 2020 Epidemiological, virological and serological features of COVID-19
 419 cases in people living with HIV in Wuhan City: A population-based cohort study. *Clin*420 *Infect Dis*, ciaa1186. (doi:10.1093/cid/ciaa1186)
- 32. Achan J *et al.* 2022 Current malaria infection, previous malaria exposure, and clinical
 profiles and outcomes of COVID-19 in a setting of high malaria transmission: an
 exploratory cohort study in Uganda. *The Lancet Microbe* 3, e62–e71.
- 424 (doi:10.1016/S2666-5247(21)00240-8)
- 33. Taylor L. 2021 Covid-19: Why Peru suffers from one of the highest excess death rates in
 the world. *BMJ* 372, n611. (doi:10.1136/bmj.n611)
- 427 34. Cabore JW *et al.* 2022 COVID-19 in the 47 countries of the WHO African region: a
 428 modelling analysis of past trends and future patterns. *The Lancet Global Health* **10**,
 429 e1099–e1114. (doi:10.1016/S2214-109X(22)00233-9)

430